Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 14/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9068601 | 0.86 | ABL1 (0.60) | ABL1 | |
| SCHEMBL9068495 | 0.85 | ABL1 (0.58) | ABL1 | |
| SCHEMBL9068609 | 0.85 | ABL1 (0.41) | ABL1 | |
| SCHEMBL9068458 | 0.83 | ABL1 (0.43) | ABL1 | |
| SCHEMBL12229502 | 0.83 | ABL1 (0.40) | ABL1 | |
| SCHEMBL9068545 | 0.82 | ABL1 (0.42) | ABL1 | |
| SCHEMBL13788311 | 0.82 | ABL1 (0.40) | ABL1 | |
| SCHEMBL13953891 | 0.82 | ABL1 (0.42) | ABL1 | |
| SCHEMBL8997999 | 0.82 | PIK3CA (0.46) | PIK3CAMAPK8MAPK9MAPK10ABL1 | |
| SCHEMBL13953889 | 0.81 | ABL1 (0.45) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188095-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | PIK3CA 472/4885MAPK8 3154/4885MAPK9 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.